Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.
K. Sreedhara Ranganath Pai
Advertisement
K. Sreedhara Ranganath Pai, PhD, is professor, epartment of Pharmacology, Manipal Academy of Higher Education
Articles by K. Sreedhara Ranganath Pai
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Advertisement
Latest Updated Articles
Review of SUT Adoption in Biopharma ManufacturingPublished: March 15th 2024 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
5
